Zullo F, Pellicano M, De Stefano R, Zupi E, Mastrantonio P
Department of Gynecologic and Pediatric Sciences, Reggio Calabria University, Catanzaro, Italy.
Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):108-12. doi: 10.1016/s0002-9378(98)70635-0.
Aims of our study were as follows: (1) to evaluate the therapeutic efficacy of the preoperative administration of a gonadotropin-releasing hormone analog before laparoscopic myomectomy and (2) to assess whether any ultrasonographic parameter of the fibroids (number, size, Doppler velocimetry, or echogenicity) was of prognostic value.
A prospective randomized study was performed on 67 patients with symptomatic uterine fibroids that were mainly intramural; these patients were undergoing laparoscopic myomectomy. Patients were randomized either to preoperative administration of two injections of a depot formulation of leuprolide acetate 28 days apart (group A, n = 35) or to direct surgery (group B, n = 32). In each group we studied the number, volume, and echogenicity of the larger fibroids; the resistance index of uterine arteries and of fibroid vessels; hematologic parameters; operative time; and blood loss.
The two groups did not differ significantly in basal ultrasonographic parameters and hematologic data. Postoperatively, the red blood cell count and the serum hemoglobin and iron levels were significantly (p < 0.05) lower in group B. Both blood loss (p < 0.01) and operative time (p < 0.05) were significantly lower in group A. However, the operative time was significantly longer when the main fibroid was markedly hypoechoic, probably because the increased softness of the tumor after leuprolide acetate pretreatment makes its enucleation much more cumbersome.
Our data confirm the therapeutic efficacy of preoperative administration of a gonadotropin-releasing hormone analog before laparoscopic myomectomy in reducing the blood loss and in decreasing the operative time. This preoperative course of leuprolide acetate in hypoechoic fibroids, because of the further reduction of the density of the myomas, causes a significant (p < 0.05) increase in operative time.
本研究的目的如下:(1)评估腹腔镜子宫肌瘤切除术前行促性腺激素释放激素类似物预处理的治疗效果;(2)评估肌瘤的任何超声参数(数量、大小、多普勒测速或回声性)是否具有预后价值。
对67例有症状的子宫肌瘤患者(主要为肌壁间肌瘤)进行了一项前瞻性随机研究,这些患者即将接受腹腔镜子宫肌瘤切除术。患者被随机分为两组,一组在术前28天分别注射两次长效醋酸亮丙瑞林(A组,n = 35),另一组直接进行手术(B组,n = 32)。在每组中,我们研究了较大肌瘤的数量、体积和回声性;子宫动脉和肌瘤血管的阻力指数;血液学参数;手术时间和失血量。
两组在基础超声参数和血液学数据方面无显著差异。术后,B组的红细胞计数、血清血红蛋白和铁水平显著降低(p < 0.05)。A组的失血量(p < 0.01)和手术时间(p < 0.05)均显著低于B组。然而,当主要肌瘤明显低回声时,手术时间显著延长,可能是因为醋酸亮丙瑞林预处理后肿瘤变软,使其摘除更加繁琐。
我们的数据证实了腹腔镜子宫肌瘤切除术前行促性腺激素释放激素类似物预处理在减少失血量和缩短手术时间方面的治疗效果。对于低回声肌瘤,术前使用醋酸亮丙瑞林由于肌瘤密度进一步降低,导致手术时间显著延长(p < 0.05)。